Singapore-based TauRx Therapeutics Ltd., just announced that they are beginning two global clinical trials for Alzheimer’s disease. The trials will focus on the use of TauRx’s Tau Aggregation Inhibitor (TAI) therapy, LMTX, which targets the disaggregation of protein aggregates of tau. In the Phase II clinical trial, LMTX reduced the rate of Alzheimer’s disease progression by 90%. LMTX also targets the disaggregation of protein aggregates of TDP-43, which are found in certain cases of FTD and ALS. In September of this year, TauRx launched a Phase III clinical trial to evaluate the efficacy and safety of LMTX for the treatment of behavioural variant frontotemporal dementia (bvFTD). The study is enrolling 180 people in the US, UK, Canada, Germany, Australia, Singapore and the Netherlands.
Click here to read more.Share this: